Cargando…

The role of ubiquitination in tumorigenesis and targeted drug discovery

Ubiquitination, an important type of protein posttranslational modification (PTM), plays a crucial role in controlling substrate degradation and subsequently mediates the “quantity” and “quality” of various proteins, serving to ensure cell homeostasis and guarantee life activities. The regulation of...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Lu, Meng, Tong, Chen, Lei, Wei, Wenyi, Wang, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048745/
https://www.ncbi.nlm.nih.gov/pubmed/32296023
http://dx.doi.org/10.1038/s41392-020-0107-0
_version_ 1783502323885015040
author Deng, Lu
Meng, Tong
Chen, Lei
Wei, Wenyi
Wang, Ping
author_facet Deng, Lu
Meng, Tong
Chen, Lei
Wei, Wenyi
Wang, Ping
author_sort Deng, Lu
collection PubMed
description Ubiquitination, an important type of protein posttranslational modification (PTM), plays a crucial role in controlling substrate degradation and subsequently mediates the “quantity” and “quality” of various proteins, serving to ensure cell homeostasis and guarantee life activities. The regulation of ubiquitination is multifaceted and works not only at the transcriptional and posttranslational levels (phosphorylation, acetylation, methylation, etc.) but also at the protein level (activators or repressors). When regulatory mechanisms are aberrant, the altered biological processes may subsequently induce serious human diseases, especially various types of cancer. In tumorigenesis, the altered biological processes involve tumor metabolism, the immunological tumor microenvironment (TME), cancer stem cell (CSC) stemness and so on. With regard to tumor metabolism, the ubiquitination of some key proteins such as RagA, mTOR, PTEN, AKT, c-Myc and P53 significantly regulates the activity of the mTORC1, AMPK and PTEN-AKT signaling pathways. In addition, ubiquitination in the TLR, RLR and STING-dependent signaling pathways also modulates the TME. Moreover, the ubiquitination of core stem cell regulator triplets (Nanog, Oct4 and Sox2) and members of the Wnt and Hippo-YAP signaling pathways participates in the maintenance of CSC stemness. Based on the altered components, including the proteasome, E3 ligases, E1, E2 and deubiquitinases (DUBs), many molecular targeted drugs have been developed to combat cancer. Among them, small molecule inhibitors targeting the proteasome, such as bortezomib, carfilzomib, oprozomib and ixazomib, have achieved tangible success. In addition, MLN7243 and MLN4924 (targeting the E1 enzyme), Leucettamol A and CC0651 (targeting the E2 enzyme), nutlin and MI‐219 (targeting the E3 enzyme), and compounds G5 and F6 (targeting DUB activity) have also shown potential in preclinical cancer treatment. In this review, we summarize the latest progress in understanding the substrates for ubiquitination and their special functions in tumor metabolism regulation, TME modulation and CSC stemness maintenance. Moreover, potential therapeutic targets for cancer are reviewed, as are the therapeutic effects of targeted drugs.
format Online
Article
Text
id pubmed-7048745
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-70487452020-03-05 The role of ubiquitination in tumorigenesis and targeted drug discovery Deng, Lu Meng, Tong Chen, Lei Wei, Wenyi Wang, Ping Signal Transduct Target Ther Review Article Ubiquitination, an important type of protein posttranslational modification (PTM), plays a crucial role in controlling substrate degradation and subsequently mediates the “quantity” and “quality” of various proteins, serving to ensure cell homeostasis and guarantee life activities. The regulation of ubiquitination is multifaceted and works not only at the transcriptional and posttranslational levels (phosphorylation, acetylation, methylation, etc.) but also at the protein level (activators or repressors). When regulatory mechanisms are aberrant, the altered biological processes may subsequently induce serious human diseases, especially various types of cancer. In tumorigenesis, the altered biological processes involve tumor metabolism, the immunological tumor microenvironment (TME), cancer stem cell (CSC) stemness and so on. With regard to tumor metabolism, the ubiquitination of some key proteins such as RagA, mTOR, PTEN, AKT, c-Myc and P53 significantly regulates the activity of the mTORC1, AMPK and PTEN-AKT signaling pathways. In addition, ubiquitination in the TLR, RLR and STING-dependent signaling pathways also modulates the TME. Moreover, the ubiquitination of core stem cell regulator triplets (Nanog, Oct4 and Sox2) and members of the Wnt and Hippo-YAP signaling pathways participates in the maintenance of CSC stemness. Based on the altered components, including the proteasome, E3 ligases, E1, E2 and deubiquitinases (DUBs), many molecular targeted drugs have been developed to combat cancer. Among them, small molecule inhibitors targeting the proteasome, such as bortezomib, carfilzomib, oprozomib and ixazomib, have achieved tangible success. In addition, MLN7243 and MLN4924 (targeting the E1 enzyme), Leucettamol A and CC0651 (targeting the E2 enzyme), nutlin and MI‐219 (targeting the E3 enzyme), and compounds G5 and F6 (targeting DUB activity) have also shown potential in preclinical cancer treatment. In this review, we summarize the latest progress in understanding the substrates for ubiquitination and their special functions in tumor metabolism regulation, TME modulation and CSC stemness maintenance. Moreover, potential therapeutic targets for cancer are reviewed, as are the therapeutic effects of targeted drugs. Nature Publishing Group UK 2020-02-29 /pmc/articles/PMC7048745/ /pubmed/32296023 http://dx.doi.org/10.1038/s41392-020-0107-0 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Review Article
Deng, Lu
Meng, Tong
Chen, Lei
Wei, Wenyi
Wang, Ping
The role of ubiquitination in tumorigenesis and targeted drug discovery
title The role of ubiquitination in tumorigenesis and targeted drug discovery
title_full The role of ubiquitination in tumorigenesis and targeted drug discovery
title_fullStr The role of ubiquitination in tumorigenesis and targeted drug discovery
title_full_unstemmed The role of ubiquitination in tumorigenesis and targeted drug discovery
title_short The role of ubiquitination in tumorigenesis and targeted drug discovery
title_sort role of ubiquitination in tumorigenesis and targeted drug discovery
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048745/
https://www.ncbi.nlm.nih.gov/pubmed/32296023
http://dx.doi.org/10.1038/s41392-020-0107-0
work_keys_str_mv AT denglu theroleofubiquitinationintumorigenesisandtargeteddrugdiscovery
AT mengtong theroleofubiquitinationintumorigenesisandtargeteddrugdiscovery
AT chenlei theroleofubiquitinationintumorigenesisandtargeteddrugdiscovery
AT weiwenyi theroleofubiquitinationintumorigenesisandtargeteddrugdiscovery
AT wangping theroleofubiquitinationintumorigenesisandtargeteddrugdiscovery
AT denglu roleofubiquitinationintumorigenesisandtargeteddrugdiscovery
AT mengtong roleofubiquitinationintumorigenesisandtargeteddrugdiscovery
AT chenlei roleofubiquitinationintumorigenesisandtargeteddrugdiscovery
AT weiwenyi roleofubiquitinationintumorigenesisandtargeteddrugdiscovery
AT wangping roleofubiquitinationintumorigenesisandtargeteddrugdiscovery